Recursion Pharmaceuticals (RXRX) reported a Q4 loss Wednesday of $0.21 per diluted share, narrowing from a loss of $0.53 a year earlier.

Analysts polled by FactSet expected a loss of $0.31.

Revenue for the quarter ended Dec. 31 was $35.5 million, up from $4.5 million a year earlier.

Analysts surveyed by FactSet expected $24.5 million.

As of Dec. 31, Recursion said it had $753.9 million in cash and cash equivalents, which it expects to provide it with a cash runway through early 2028.

Shares of the company were up more than 12% in recent Wednesday premarket activity.